EMEA-001766-PIP01-15-M01

Key facts

Active substance
  • bictegravir
  • emtricitabine
  • tenofovir alafenamide
Therapeutic area
Infectious diseases
Decision number
P/0339/2016
PIP number
EMEA-001766-PIP01-15-M01
Pharmaceutical form(s)
  • Age-appropriate oral formulation
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Gilead Sciences International Ltd.
United Kingdom
Tel. +44 1223897300
Fax +44 1223897284
E-mail: regulatory.pip@gilead.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating